Navigation Links
Insmed to Host Third Quarter 2010 Conference Call

RICHMOND, Va., Oct. 26 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday, November 3rd, at 8:30 AM ET, to discuss its financial results for the third quarter 2010.  Insmed intends to issue its quarterly financial results press release before the market opens on November 3rd.

To participate in the live conference call, please dial 866-356-4281 (U.S. callers) or 617-597-5395 (international), and provide passcode 61751565.  A live webcast of the call will also be available at  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on November 3rd, at 888-286-8010 (U.S. callers) or 617-801-6888 (international), using passcode 28300679.

About InsmedInsmed Inc. is a biopharmaceutical company with unique protein development experience and a proprietary protein platform aimed at niche markets with unmet medical needs.  For more information, please visit

Forward-Looking Statements This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to business strategies, plans and objectives of management and our strategic review process, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, we may be unsuccessful in identifying or reaching agreement with acquisition or merger candidates, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2009.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.Investor Relations Contact:Brian Ritchie – FD212-850-5683brian.ritchie@fd.comMedia Contact:Irma Gomez-Dib –

SOURCE Insmed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
2. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
3. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
4. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
5. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
6. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
7. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
8. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
9. West to Host 2010 Third Quarter Conference Call
10. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
11. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
Breaking Medicine Technology:
(Date:11/29/2015)... Aliso Viejo, CA (PRWEB) , ... November 29, ... ... is an all new and unique analog distortion effect tool designed specially for ... to their footage, and create limiltess looks with the easy-to-use modification controls. Destoying ...
(Date:11/28/2015)... ... November 28, 2015 , ... Safe storage for contraceptive devices ... inventors, one from Lakewood, New Jersey and the other from Bradley Beach, New Jersey, ... to save the expense of having to replace NuvaRings more often than necessary. As ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... ... , ... The rapid speed at which Americans are aging ... is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming more prevalent. ... part of this equation: 80 percent of medical care occurs in the home, ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
Breaking Medicine News(10 mins):